Novel expression of cyclin-dependent kinase inhibitors in human B-cell precursors

Objective. Eukaryotic cell division is regulated by cyclins, cyclin-dependent kinases (CDF;), and cyclin-dependent kinase inhibitors (CECI), Genes encoding these proteins are mutated or deleted in many types of cancer. For example, 20%-30% of B-lineage acute lymphoblastic leukemias (ALL) have deletions in the CKI known as INK4a. The contribution of INK4a deletions to the progression of B-Lineage ALL is uncertain, partially due to a paucity of data on expression in normal B-cell precursors. We therefore conducted a comparative analysis of normal and leukemic human B-cell development for the expression of cyclins, CDK, and CKI. Materials and Methods. Specific stages of human B-cell development from normal bone marrow were purified by fluorescence-activated cell sorting. The sorted populations and B-lineage ALL cell lines (BLIN-1, 2, 3, 4) sere examined for expression of cyclins, CDK, and CE;I by reverse transcriptase polymerase chain reaction (RT-PCR) and Western blotting. Results. RT-PCR analysis showed that cyclin D2, cyclin D3, CDK4, and CDK6 were ubiquitously. expressed in normal B-cell development and in the BLIN ALL cell lines. The p19(INK4d) CKI was the most commonly expressed member of the INK4 family, whereas p16(INK4a) was more weakly and variably expressed. Expression of the p57(KIP2) CKI varied as a function of the stage of B-cell development, Analysis of normal B-cell precursors by Western blotting indicated that CDK4, CDK6, p19(INK4d), and p57(KIP2) were expressed, whereas p16(INK4a) was not detected. Conclusion. Cyclin D/CDK expression in normal and leukemic human II-cell precursors is similar to expression of these proteins in human and murine mature B cells. In contrast, the ubiquitous expression of p19(INK4d) has not been previously described in human or murine B-Lineage cells. Our results suggest that loss of INK4a may only minimally contribute to tumor cell progression in B-linkage,ALL, since expression of INK4d could provide a compensatory function as a cyclin-dependent kinase inhibitor. (C) 2001 International Society for Experimental Hematology. Published by Elsevier Science Inc.